A multicenter, randomized study to evaluate the efficacy and safety of mesalamine suppositories 1 g at bedtime and 500 mg twice daily in patients with active mild-to-moderate ulcerative proctitis

Digestive Diseases and Sciences

Volumn 56, Issue 2, 2011, Pages 513-522

  Lamet, Mark ^a  

^a Center for Gastrointestinal Disorders   (United States)

Author keywords

Inflammatory bowel disease; Mesalamine; Suppository; Ulcerative proctitis

Indexed keywords

MESALAZINE;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BEDTIME DOSAGE; BREAST DISEASE; BRONCHOSPASM; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DIARRHEA; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; FEMALE; FLATULENCE; HUMAN; INFECTION; INFESTATION; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NAUSEA; NEUROLOGIC DISEASE; PARALLEL DESIGN; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROCTITIS; RANDOMIZED CONTROLLED TRIAL; RECTUM HEMORRHAGE; REMISSION; RESPIRATORY TRACT DISEASE; SKIN DISEASE; ULCERATIVE PROCTITIS;

ADOLESCENT; ADULT; AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MESALAMINE; MIDDLE AGED; PROCTITIS; SUPPOSITORIES; YOUNG ADULT;

EID: 79952449301     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-010-1334-y     Document Type: Article

References (38)

1. MD Regueiro 2004 Diagnosis and treatment of ulcerative proctitis J Clin Gastroenterol 38 733 740 10.1097/01.mcg.0000139178.33502.a3 10.1097/01.mcg. 0000139178.33502.a3 15365396 (Pubitemid 39274171)
2. SB Hanauer 2001 Update on medical management of inflammatory bowel disease: ulcerative colitis Rev Gastroenterol Disord 1 169 176 1:STN:280:DC%2BD38znsVKksA%3D%3D 12120183
3. A Kornbluth DB Sachar 2010 Ulcerative colitis practice guidelines in adults: American college of gastroenterology, practice parameters committee Am J Gastroenterol 105 501 523 10.1038/ajg.2009.727 10.1038/ajg.2009.727 20068560
4. LJ Herrinton L Liu JD Lewis PM Griffin J Allison 2008 Incidence and prevalence of inflammatory bowel disease in a Northern California managed care organization, 1996-2002 Am J Gastroenterol 103 1998 2006 10.1111/j.1572-0241. 2008.01960.x 18796097
5. SC Ng MA Kamm 2009 Therapeutic strategies for the management of ulcerative colitis Inflamm Bowel Dis 15 935 950 10.1002/ibd.20797 10.1002/ibd.20797 18985710
6. SL James PM Irving RB Gearry PR Gibson 2008 Management of distal ulcerative colitis: frequently asked questions analysis Intern Med J 38 114 119 10.1111/j.1445-5994.2007.01601.x 1:STN:280:DC%2BD1c7jtFyhsg%3D%3D 10.1111/j.1445-5994.2007.01601.x 18290827 (Pubitemid 351257958)
7. PL Lakatos L Lakatos 2008 Ulcerative proctitis: a review of pharmacotherapy and management Expert Opin Pharmacother 9 741 749 10.1517/14656566.9.5.741 1:CAS:528:DC%2BD1cXjtlWis70%3D 10.1517/14656566.9.5.741 18345952 (Pubitemid 351566191)
8. ® (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study Gut 54 960 965 10.1136/gut.2004.060103 1:CAS:528:DC%2BD2MXmsFKqsbc%3D 10.1136/gut.2004.060103 15951542 (Pubitemid 40873909)
9. M Campieri P Gionchetti A Belluzzi, et al. 1990 Topical treatment with 5-aminosalicylic in distal ulcerative colitis by using a new suppository preparation: a double-blind placebo controlled trial Int J Colorectal Dis 5 79 81 10.1007/BF00298473 1:STN:280:DyaK3c3ptlGqtw%3D%3D 10.1007/BF00298473 2193075 (Pubitemid 20182676)
10. P Gionchetti F Rizzello A Venturi, et al. 1997 Comparison of mesalazine suppositories in proctitis and distal proctosigmoiditis Aliment Pharmacol Ther 11 1053 1057 10.1046/j.1365-2036.1997.00259.x 1:CAS:528:DyaK1cXhsVOgtA%3D%3D 10.1046/j.1365-2036.1997.00259.x 9663829 (Pubitemid 27525110)
11. IC Lawrance TS Copeland 2008 Rectal tacrolimus in the treatment of resistant ulcerative proctitis Aliment Pharmacol Ther 28 1214 1220 10.1111/j.1365-2036.2008.03841.x 1:CAS:528:DC%2BD1cXhsFWrt7rF 10.1111/j.1365-2036.2008.03841.x 18761706
12. D Lucidarme P Marteau M Foucault B Vautrin B Filoche 1997 Efficacy and tolerance of mesalazine suppositories versus hydrocortisone foam in proctitis Aliment Pharmacol Ther 11 335 340 10.1046/j.1365-2036.1997.126297000.x 1:CAS:528:DyaK2sXjt1entLY%3D 10.1046/j.1365-2036.1997.126297000.x 9146772 (Pubitemid 27183513)
13. P Marteau C Florent 2000 Comparative, open, randomized trial of the efficacy and tolerance of slow-release 5-ASA suppositories once daily versus conventional 5-ASA suppositories twice daily in the treatment of active cryptogenic proctitis: French Pentasa Study Group Am J Gastroenterol 95 166 170 10.1111/j.1572-0241.2000.01679.x 1:CAS:528:DC%2BD3cXptlemtw%3D%3D 10.1111/j.1572-0241.2000.01679.x 10638577 (Pubitemid 30041553)
14. JK Marshall EJ Irvine 2000 Putting rectal 5-aminosalicylic acid in its place: the role in distal ulcerative colitis Am J Gastroenterol 95 1628 1636 1:CAS:528:DC%2BD3cXlslakt7Y%3D 10.1111/j.1572-0241.2000.02180.x 10925961 (Pubitemid 30484995)
15. RA van Hogezand PA van Hees JP van Gorp, et al. 1988 Double-blind comparison of 5-aminosalicylic acid and acetyl-5-aminosalicylic acid suppositories in patients with idiopathic proctitis Aliment Pharmacol Ther 2 33 40 10.1111/j.1365-2036.1988.tb00668.x 2979230
16. JH Rubenstein AK Waljee JM Jeter FS Velayos U Ladabaum PD Higgins 2009 Cost effectiveness of ulcerative colitis surveillance in the setting of 5-aminosalicylates Am J Gastroenterol 104 2222 2232 10.1038/ajg.2009.264 10.1038/ajg.2009.264 19491824
17. GC Kaiser F Yan DB Polk 1999 Mesalamine blocks tumor necrosis factor growth inhibition and nuclear factor κB activation in mouse colonocytes Gastroenterology 116 602 609 10.1016/S0016-5085(99)70182-4 1:CAS:528: DyaK1MXhvVOnt7k%3D 10.1016/S0016-5085(99)70182-4 10029619 (Pubitemid 29106768)
18. T Narisawa Y Fukaura 2003 Prevention by intrarectal 5-aminosalicylic acid of N-methylnitrosourea-induced colon cancer in F344 rats Dis Colon Rectum 46 900 903 10.1007/s10350-004-6681-3 10.1007/s10350-004-6681-3 12847363 (Pubitemid 36875484)
19. C Stolfi M Sarra R Caruso, et al. 2010 Inhibition of colon carcinogenesis by 2-methoxy-5-amino-N-hydroxybenzamide, a novel derivative of mesalamine Gastroenterology 138 221 230 10.1053/j.gastro.2009.08.062 1:CAS:528: DC%2BC3cXht1ajtr8%3D 10.1053/j.gastro.2009.08.062 19737563
20. Lamet M, Ptak T, Dallaire C, et al.; Mesalamine Study Group. Efficacy and safety of mesalamine 1 g HS versus 500 mg BID suppositories in mild to moderate ulcerative proctitis: a multicenter randomized study. Inflamm Bowel Dis. 2005;11:625-630. doi: 10.1097/01.MIB.0000171277.70404.40. (Pubitemid 40961075)
21. LG Jørgensen L Fredholm P Hyltoft Petersen H Hey P Munkholm I Brandslund 2005 How accurate are clinical activity indices for scoring of disease activity in inflammatory bowel disease (IBD)? Clin Chem Lab Med 43 403 411 10.1515/CCLM.2005.073 10.1515/CCLM.2005.073 15899657 (Pubitemid 41460647)
22. LR Sutherland F Martin S Greer, et al. 1987 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis Gastroenterology 92 1894 1898 1:STN:280:DyaL2s7ptFKlsg%3D%3D 3569765 (Pubitemid 17072238)
23. K Geboes R Ridell A Ost B Jensfelt T Persson R Lofberg 2000 A reproducible grading scale for histological assessment of inflammation in ulcerative colitis Gut 47 404 409 10.1136/gut.47.3.404 1:STN:280: DC%2BD3cvjs1GitQ%3D%3D 10.1136/gut.47.3.404 10940279
24. RH Riddell H Goldman DF Ransohoff, et al. 1983 Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications Hum Pathol 14 931 968 10.1016/S0046-8177(83)80175-0 1:STN:280:DyaL2c%2FjtVKqsQ%3D%3D 10.1016/S0046-8177(83)80175-0 6629368
25. RJ Schlemper RH Riddell Y Kato, et al. 2000 The Vienna classification of gastrointestinal epithelial neoplasia Gut 47 251 255 10.1136/gut.47.2.251 1:STN:280:DC%2BD3cvgsVWjsA%3D%3D 10.1136/gut.47.2.251 10896917 (Pubitemid 30489769)
26. RB D'Agostino Sr JM Massaro LM Sullivan 2003 Non-inferiority trials: design concepts and issues-the encounters of academic consultants in statistics Stat Med 22 169 186 10.1002/sim.1425 10.1002/sim.1425 12520555 (Pubitemid 36163579)
27. M Regueiro EV Loftus Jr AH Steinhart RD Cohen 2006 Inflammatory Bowel Disease Center. Clinical guidelines for the medical management of left-sided ulcerative colitis and ulcerative proctitis: summary statement Inflamm Bowel Dis 12 972 978 10.1097/01.mib.0000231496.92013.85 10.1097/01.mib.0000231496.92013. 85 17012968 (Pubitemid 44498286)
28. PD Higgins DT Rubin K Kaulback PS Schoenfield SV Kane 2009 Systematic review: impact of non-adherence to 5-aminosalicylic acid products on the frequency and cost of ulcerative colitis flares Aliment Pharmacol Ther 29 247 257 10.1111/j.1365-2036.2008.03865.x 1:STN:280:DC%2BD1M%2FlvVyqtw%3D%3D 10.1111/j.1365-2036.2008.03865.x 18945258
29. A Cortot D Maetz E Degoutte, et al. 2008 Mesalamine foam enema versus mesalamine liquid enema in active left-sided ulcerative colitis Am J Gastroenterol 103 3106 3114 10.1111/j.1572-0241.2008.02152.x 10.1111/j.1572-0241.2008.02152.x 19086960
30. T Molnár K Farkas F Nagy I Németh T Wittmann 2009 Topically administered infliximab can work in ulcerative proctitis despite the ineffectiveness of intravenous induction therapy Am J Gastroenterol 104 1857 1858 10.1038/ajg.2009.147 19436284
31. M Regueiro EV Loftus Jr AH Steinhart RD Cohen 2006 Medical management of left-sided ulcerative colitis and ulcerative proctitis: critical evaluation of therapeutic trials Inflamm Bowel Dis 12 979 994 10.1097/01.mib.0000231495.92013. 5e 10.1097/01.mib.0000231495.92013.5e 17012969 (Pubitemid 44498287)
32. G d'Albasio P Paoluzi M Campieri, et al. 1998 Maintenance treatment of ulcerative proctitis with mesalazine suppositories: a double-blind placebo-controlled trial Am J Gastroenterol 93 799 803 9625131 (Pubitemid 29063925)
33. K Tokui Y Asai T Arakawa T Matsumoto T Nabeshima 2002 Comparative absorption of 5-aminosalicylic acid (5-ASA) after administration of a 5-ASA enema and salazosulfapyridine (SASP) after an SASP suppository in Japanese volunteers Biol Pharm Bull 25 264 267 10.1248/bpb.25.264 1:CAS:528: DC%2BD38XkslWlu74%3D 10.1248/bpb.25.264 11853180 (Pubitemid 39592119)
34. TB Vree E Dammers PS Exler RA Maes 2000 Mono- and biphasic plasma concentration-time curves of mesalazine from a 500 mg suppository in healthy male volunteers controlled by the time of defecation before dosing J Pharm Pharmacol 52 645 652 10.1211/0022357001774471 1:CAS:528:DC%2BD3cXkslOhsLk%3D 10.1211/0022357001774471 10875540 (Pubitemid 30410077)
35. TB Vree E Dammers PS Exler RA Maes 2000 Liver and gut mucosa acetylation of mesalazine in healthy volunteers Int J Clin Pharmacol Ther 38 514 522 1:CAS:528:DC%2BD38XovVyruw%3D%3D 11097143
36. G D'Albasio F Pacini E Camarri, et al. 1997 Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: a randomized double-blind study Am J Gastroenterol 92 1143 1147 9219787 (Pubitemid 27304810)
37. LP Piodi FM Ulivieri L Cermesoni BM Cesana 2004 Long-term intermittent treatment with low-dose 5-aminosalicylic enemas is efficacious for remission maintenance in ulcerative colitis Scand J Gastroenterol 39 154 157 10.1080/00365520310008133 1:CAS:528:DC%2BD2cXisFKmu7w%3D 10.1080/ 00365520310008133 15000277 (Pubitemid 38253627)
38. TD Bolin S Wong R Crouch JL Engelman SM Riordan 2009 Appendicectomy as a therapy for ulcerative proctitis Am J Gastroenterol 104 2476 2482 10.1038/ajg.2009.388 10.1038/ajg.2009.388 19584834